TuHURA Biosciences, Inc. borrowed $650,000 on August 20, 2026, under a revolving credit facility established with Parkview Holdings One LLC in April 2026. The loan agreement provides for a maximum availability of $50 million and matures on April 21, 2031. The company intends to use the proceeds for general corporate purposes. TuHURA Biosciences operates as a clinical-stage biotechnology company focused on developing therapies for rare diseases.
